Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Money Flow Index

Score

-4.45

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 3 159.3 0.33% 0.50% 22.0% -17.2% -12.4%
SHORT 2 76.0 0.00% 0.00% 0.0% -10.3% -20.6%

Summary

Technical Analysis

Mesoblast (MSB.AX)


Indicator:

MONEY FLOW INDEX


Last Signal:

NEUTRAL


Trading: NO POSITION
Signal Strength: MEDIUM


Money Flow Index (MFI) is a volume-based indicator it could be used in technical analysis to measure the strength of money flow in and out of a security index and market. The principle of MFI calculation is a comparison of positive money flow to negative money flow. MFI is also known as volume-weighted RSI. MFI starts with the typical price for each period. The same as RSI the MFI scale is between 0 and 100.

Calculation: Money Flow Index (MFI):
1) Typical Price = (High + Low + Close)/3;
2) Raw Money Flow = Typical Price x Volume;
3) Money Flow Ratio = (14-period Positive Money Flow)/(14-period Negative Money Flow);
4) Money Flow Index = 100 - 100/(1 + Money Flow Ratio)


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Money Flow Index

Download
Company Close Change(%) Volume Value Signal
OMH OM Holdings 0.55 14.6 216,147 38.48 NEUTRAL
SMX Sms Management & Technology 0.34 13.3 103,068 40.08 NEUTRAL
ALQ ALS 9.06 12.1 3,902,789 63.32 NEUTRAL
BFC Beston Global Food 0.09 11.1 217,930 57.13 NEUTRAL
TNE Technology One 8.72 11.1 2,344,237 56.37 NEUTRAL
TWR Tower 0.67 9.8 116,137 60.05 NEUTRAL
DNK Danakali 0.64 8.5 171,076 54.81 NEUTRAL
BSE BSE 0.24 6.8 118,988 24.82 NEUTRAL
CCV Cash Converters International 0.25 6.5 1,327,868 59.88 NEUTRAL
ALL Aristocrat Leisure 33.71 6 3,327,758 60.19 NEUTRAL